Eirwen M. Miller, MD, discusses novel biomarkers that she believes will be important for endometrial cancer in the future.
Eirwen M. Miller, MD, gynecologic oncologist at Allegheny Health Network, discusses novel biomarkers that she believes will be important for endometrial cancer in the future.
According to Miller, targeted therapies have been making an impact in the endometrial cancer space. Some profound results were previously presented for patients that had mismatch repair deficient (dMMR) endometrial cancers, and these data likely will change the standard of care for that subgroup of patients
Some of the most recent approvals in the endometrial cancer space have been pembrolizumab (Keytruda) and dostarlimab (Jemperli) for patients with mismatch repair deficient (dMMR) endometrial cancers, both of which can be used alone or in combination with chemotherapy. More agents are currently in development.
With the rapid expansion of treatment options over the past few years, Miller expects to see even more agents studied and granted regulatory approval moving forward.
0:10 | In endometrial cancer, we're seeing some interest in targeted therapies. I mentioned the MMR pathway, which is definitely a target that has some FDA approvals at this time. Both pembrolizumab and dostarlimab are FDA-approved for patients with dMMR endometrial cancers, either as a treatment or in combination with chemotherapy.
0:42 | In terms of future targets that we're looking at, we have 2 phase 3 clinical trials right now, enrolling for a p53 wild-type population. One of the drugs, selinexor [Xpovio], has demonstrated a progression-free survival benefit in a p53 wild-type subgroup in a prior study. We are really exploring that subgroup of patients. I think those are probably the 2 biggest targets that we're looking at at the moment. The landscape of targeted therapy across those gynecologic malignancies is expanding rapidly. I think that we'll continue to see additional targets come to be studied and come to the market over the next 5 to 10 years.